Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 13 to 15 of 15 entries
Sorted by: Best Match Show Resources per page
Higher Desolvation Energy Reduces Molecular Recognition in Multi-Drug Resistant HIV-1 Protease.

Biology

Wang Y, Dewdney TG, Liu Z, Reiter SJ, Brunzelle JS, Kovari IA, Kovari LC.
PMID: 24832048
Biology (Basel). 2012 May 31;1(1):81-93. doi: 10.3390/biology1010081.

Designing HIV-1 protease inhibitors that overcome drug-resistance is still a challenging task. In this study, four clinical isolates of multi-drug resistant HIV-1 proteases that exhibit resistance to all the US FDA-approved HIV-1 protease inhibitors and also reduce the substrate...

Cite
Wang Y, Dewdney TG, Liu Z, et al. Higher Desolvation Energy Reduces Molecular Recognition in Multi-Drug Resistant HIV-1 Protease. Biology (Basel). 2012;1(1):81-93doi: 10.3390/biology1010081.
Wang, Y., Dewdney, T. G., Liu, Z., Reiter, S. J., Brunzelle, J. S., Kovari, I. A., & Kovari, L. C. (2012). Higher Desolvation Energy Reduces Molecular Recognition in Multi-Drug Resistant HIV-1 Protease. Biology, 1(1), 81-93. https://doi.org/10.3390/biology1010081
Wang, Yong, et al. "Higher Desolvation Energy Reduces Molecular Recognition in Multi-Drug Resistant HIV-1 Protease." Biology vol. 1,1 (2012): 81-93. doi: https://doi.org/10.3390/biology1010081
Wang Y, Dewdney TG, Liu Z, Reiter SJ, Brunzelle JS, Kovari IA, Kovari LC. Higher Desolvation Energy Reduces Molecular Recognition in Multi-Drug Resistant HIV-1 Protease. Biology (Basel). 2012 May 31;1(1):81-93. doi: 10.3390/biology1010081. PMID: 24832048; PMCID: PMC4011036.
Copy Download .nbib Format: NLM
Evaluating the cardiovascular effects of the thiazolidinediones and their place in the management of type 2 diabetes in relation to the metabolic syndrome.

Metabolic syndrome and related disorders

Drexler AJ, Nesto RW, Abrahamson MJ, Bakris G, Bell D, Brunzell J, Dandona P, Davidson J, Fonseca V, Fowler M, Frye R, Giles T, Haffner S, Hollenberg N, Hsueh W, Law R, Plutzky J, Ratner R, Reusch J, Selwyn A, Sowers J, Wyne K, Young LH.
PMID: 18370723
Metab Syndr Relat Disord. 2005;3(2):147-73. doi: 10.1089/met.2005.3.147.

BACKGROUND: The aim of this work was to review evidence on the contribution of the metabolic syndrome to diabetes and atherosclerosis, to evaluate the effects of the thiazolidinediones (TZDs) on cardiovascular risk, and to assess the clinical use of...

Cite
Drexler AJ, Nesto RW, Abrahamson MJ, et al. Evaluating the cardiovascular effects of the thiazolidinediones and their place in the management of type 2 diabetes in relation to the metabolic syndrome. Metab Syndr Relat Disord. 2005;3(2):147-73doi: 10.1089/met.2005.3.147.
Drexler, A. J., Nesto, R. W., Abrahamson, M. J., Bakris, G., Bell, D., Brunzell, J., Dandona, P., Davidson, J., Fonseca, V., Fowler, M., Frye, R., Giles, T., Haffner, S., Hollenberg, N., Hsueh, W., Law, R., Plutzky, J., Ratner, R., Reusch, J., Selwyn, A., Sowers, J., Wyne, K., & Young, L. H. (2005). Evaluating the cardiovascular effects of the thiazolidinediones and their place in the management of type 2 diabetes in relation to the metabolic syndrome. Metabolic syndrome and related disorders, 3(2), 147-73. https://doi.org/10.1089/met.2005.3.147
Drexler, Andrew J, et al. "Evaluating the cardiovascular effects of the thiazolidinediones and their place in the management of type 2 diabetes in relation to the metabolic syndrome." Metabolic syndrome and related disorders vol. 3,2 (2005): 147-73. doi: https://doi.org/10.1089/met.2005.3.147
Drexler AJ, Nesto RW, Abrahamson MJ, Bakris G, Bell D, Brunzell J, Dandona P, Davidson J, Fonseca V, Fowler M, Frye R, Giles T, Haffner S, Hollenberg N, Hsueh W, Law R, Plutzky J, Ratner R, Reusch J, Selwyn A, Sowers J, Wyne K, Young LH. Evaluating the cardiovascular effects of the thiazolidinediones and their place in the management of type 2 diabetes in relation to the metabolic syndrome. Metab Syndr Relat Disord. 2005;3(2):147-73. doi: 10.1089/met.2005.3.147. PMID: 18370723.
Copy Download .nbib Format: NLM
Cutaneous Pedal Manifestations in Patient With Hepatitis C Virus-Associated Cryoglobulinemia: Case Report and Review of Literature.

The international journal of lower extremity wounds

McEneaney PA, Nicklas BJ, Kuba JL, Rundell JD.
PMID: 33089718
Int J Low Extrem Wounds. 2020 Oct 22;1534734620961893. doi: 10.1177/1534734620961893. Epub 2020 Oct 22.

Cryoglobulinemia is an uncommon blood dyscrasia that can manifest itself in the lower extremity. Due to the insidious nature of this disease, dermatological symptoms and ulcerations can easily be mistaken for more common entities. The authors present an overview...

Cite
McEneaney PA, Nicklas BJ, Kuba JL, et al. Cutaneous Pedal Manifestations in Patient With Hepatitis C Virus-Associated Cryoglobulinemia: Case Report and Review of Literature. Int J Low Extrem Wounds. 2020;1534734620961893doi: 10.1177/1534734620961893.
McEneaney, P. A., Nicklas, B. J., Kuba, J. L., & Rundell, J. D. (2020). Cutaneous Pedal Manifestations in Patient With Hepatitis C Virus-Associated Cryoglobulinemia: Case Report and Review of Literature. The international journal of lower extremity wounds, 1534734620961893. https://doi.org/10.1177/1534734620961893
McEneaney, Patrick A, et al. "Cutaneous Pedal Manifestations in Patient With Hepatitis C Virus-Associated Cryoglobulinemia: Case Report and Review of Literature." The international journal of lower extremity wounds vol. (2020): 1534734620961893. doi: https://doi.org/10.1177/1534734620961893
McEneaney PA, Nicklas BJ, Kuba JL, Rundell JD. Cutaneous Pedal Manifestations in Patient With Hepatitis C Virus-Associated Cryoglobulinemia: Case Report and Review of Literature. Int J Low Extrem Wounds. 2020 Oct 22;1534734620961893. doi: 10.1177/1534734620961893. Epub 2020 Oct 22. PMID: 33089718.
Copy Download .nbib Format: NLM
Showing 13 to 15 of 15 entries